glp-1 cardiovascular outcomes trial august 2025 Comparative effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target emulation cohort study SELECT Trial

The primary endpoint, change of weight loss over time, was analyzed by repeated-measures ANOVA comparing patients with GLP-1-RAs plus usual care weight management (GLP-1-RA group) to patients with usual care weight management only (UCWM)

Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)

Who might benefit most

And to do this, we looked at the iqvia prescription and medical claims data, we can tag that on the basis of whether the claim came from a pharmacy setting or not

premenopausal women, older adults) Monitoring should be risk-based, not routine by default

Even in that drug class, millions of people are impacted with exclusions, and the number of people with adverse events or adverse outcomes are in the millions